LT-1339–553: RIPK1 Inhibitor Structure for Hepatic Fibrosis

A 368.4 KB PDB file contains the molecular structure of LT-1339–553, a potent RIPK1 inhibitor. The compound, developed by Ju-Lu Lu and published on figshare in May 2026, exhibited an IC50 of 4.32 nM and demonstrated antifibrotic effects in a murine model.

Use Cases

• Analyze molecular interactions based on the described PDB structure file.
• Validate structure-activity relationships based on the reported IC50 and EC50 values.
• Model drug-target binding for RIPK1 inhibitors based on the structure-based optimization mentioned.
• Study potential therapeutic mechanisms based on the described suppression of AKT/PI3K/NF-κB and IL-17 pathways.

Strengths

• The dataset provides a specific molecular structure (LT-1339–553) with reported high potency (IC50 = 4.32 nM).
• The description includes concrete in-vivo results from a murine model of hepatic fibrosis.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.

Provenance

Source

figshare

Collection Method

Structure-based optimization and experimental validation as described.

Freshness

Last updated 2026-05-16 14:09:45; freshness should be verified.